Stroke in women

Recent Patents on Cardiovascular Drug Discovery

Volumn 3, Issue 3, 2008, Pages 209-221

  Saini, Monica ^a   Shuaib, Ashfaq ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Hormonal mechanisms; Hormone replacement therapy; Sexual differences; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CLOPIDOGREL; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; PRAVASTATIN; PROGESTERONE; PROLACTIN; TESTOSTERONE; TISSUE PLASMINOGEN ACTIVATOR;

APOPTOSIS; ARTERY INTIMA PROLIFERATION; BLEEDING; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENCEPHALITIS; ENDOTHELIUM; FAMILY HISTORY; FEMALE; GENETIC RISK; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INCIDENCE; LOW DRUG DOSE; MIGRAINE; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATIENT CARE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; VASCULAR SMOOTH MUSCLE; WOMEN'S HEALTH;

CONTRACEPTIVES, ORAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RISK FACTORS; SEX CHARACTERISTICS; STROKE;

EID: 58149129520     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489008786264032     Document Type: Review

References (207)

1. Rosamund W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.
2. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA Project. Stroke 1995; 26: 361-367.
3. Nishi N. Baseline cardiovascular risk factors and stroke mortality by municipality population size in a 19-year follow-up study-NIPPON DATA80. J Epidemiol 2008; 18(4): 135-143.
4. Morgenstern LB, Spears WD, Goff DC, Grotta JC, Nichaman MZ. African Americans and women have the highest stroke mortality in Texas. Stroke 1997; 28: 15-18.
5. Sheikh K, Bullock CM. Effect of measurement on sex difference in stroke mortality. Stroke 2007; 38: 1085.
6. Ferris A, Robertson RM, Fabunmi R, Mosca L. American Heart Association and American Stroke Association national survey of stroke risk awareness among women. Circulation 2005; 111: 1321-1326.
7. Petitti DB, Sidney S, Quesenberry CP Jr., Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 1997; 28: 280-283.
8. Rozenthul-Sorokin N, Ronen R, Tamir A, Geva H, Eldar R. Stroke in the young in Israel: Incidence and outcomes. Stroke 1996; 27: 838-841.
9. Bots ML, Looman SJ, Koudstaal PJ, Hofman A, Hoes AW, Grobbee DE. Prevalence of stroke in the general population. Stroke 1996; 27: 1499-1501.
10. Carlo AD, Lamassa M, Baldereschi M, et al. Sex Differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe. Stroke 2003; 34: 1114.
11. Horner S, Niederkorn K, Schnabl S, Fazekas F. Gender aspects of Ischemic stroke. An analysis of the Austrian Stroke-Unit Registry. Wien Med Wochenschr 2008; 158(15-16): 446-452.
12. Andersen MN, Andersen KK, Kammersgaard LP, Olsen TS. Sex differences in stroke survival: 10-year follow-up of the Copenhagen stroke study cohort. J Stroke Cerebrovasc Dis 2005; 14(5): 215-220.
13. Roquer J, Campello AR, Gomis M. Sex differences in first-ever acute stroke. Stroke 2003; 34: 1581.
14. Kitamura A, Nakagawa Y, Sato M, et al. Proportions of stroke subtypes among men and women ≥ 40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke 2006; 37: 1374.
15. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Arch Intern Med 1990; 150: 2557-2562.
16. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-1109.
17. Sullivan JM, El-Zeky F, Zwaag RV, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997; 79: 847-850.
18. Hulley S, Grady D, Bush T, et al. Randomized trial of Estrogen plus Progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
19. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217-221.
20. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. NEJM 2001; 25(345): 1243-1249.
21. The Women's Health Initiative Steering Committee. Effects of conjugated equine Estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-1712.
22. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-716.
23. Langer RD, Pradhan AD, Lewis CE, et al. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease: The Women's Health Initiative Observational Study. Thromb Haemost 2005; 93: 1108-1116.
24. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8(1): 3-12.
25. Brownley KA, Hinderliter AL, West SG, et al. Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: Differences associated with years since menopause. Am J Obstet Gynecol 2004; 190: 1052-1058.
26. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: Results of a case-control study. BMJ 1993; 306: 956-963.
27. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000; 284: 72-78.
28. Hannaford P, Croft P, Kay C. Oral contraception and stroke: Evidence from the Royal College of General Practitioners' oral contraception study. Stroke 1994; 25: 935-942.
29. Schwartz SM, Pettiti DB, Siscovick DS, et al. Stroke and use of low dose oral contraceptives in young women: A pooled analysis of two US studies. Stroke 1998; 29: 2277-2284.
30. Kemmeren JM, Tanis BC, van den Bosch MA, et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202-1208.
31. Heinemann LAJ, Lewis MA, Thorogood M, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher R. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1997; 315: 1502-1504.
32. Heinemann L In: Michael F Ed, Epidemiological assessment of cardiovascular effects of hormonal contraception: Safety requirements for contraceptive steroids. New York, Cambridge University Press 1989: 113-125.
33. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348 (9026): 498-505.
34. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335(1): 8-15.
35. Siritho S, Thrift AG, McNeil JJ, You RX, Davis SM, Donnan GA. Risk of ischemic stroke among users of the oral contraceptive pill. Stroke 2003; 34(7): 1575-1580.
36. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109: 339-346.
37. Jick SS, Jick H. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy 2007; 27(2): 218-220.
38. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 2006; 91(6): 844-847.
39. Pruissen DMO, Slooter AJC, Rosendaal FR, Van der Graaf Y, Algra A. Coagulation factor XIII gene variation, oral contraceptives and risk of ischemic stroke. Blood 2008; 111: 1282-1286.
40. MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007; 38(9): 2438-2445.
41. Schueller PO, Feuring M, Sharkova Y, Grimm W, Christ M. Effects of synthetic progestagens on autonomic tone, neurohormones and C-reactive protein levels in young healthy females in reproductive age. Int J Cardiol 2006; 111: 42-48.
42. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JS, Raitakari OT. Distribution and determinants of serum high-sensitive Creactive protein in a population of young adults: The cardiovascular risk in young Finns study. J Intern Med 2005; 258: 428-434.
43. Döring A, Fröhlich M, Löwel H, Koenig W. Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 2004; 172: 281-286.
44. Bukowska H, Stanosz S, Zochowska E, et al. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? Metab Clin Exp 2005; 54: 72-78.
45. Prestwood KM, Unson C, Kulldorff M, Cushman M. The effect of different doses of micronized 17-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci 2004; 59: 827-832.
46. Sumino H, Ichikawa S, Sawada Y, et al. Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women. Thromb Res 2005; 115: 359-366.
47. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aich M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
48. Cauci S, Di Santolo M, Culhane JF, et al. Effects of third generation oral contraceptives on high sensitivity C-Reactive protein and homocysteine in young women. Obs Gynae 2008; 111(4): 857-864.
49. Wiebers DO, Whisnant JP. The incidence of stroke among pregnant women in Rochester, Minn., 1955 through 1979. JAMA 1985; 254: 3055-3057.
50. James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005; 106(3): 509-516.
51. Lanska DJ, Kryscio RJ. Stroke and intracranial venous thrombosis during pregnancy and puerperium. Neurology 1998; 51(6): 1622-1628.
52. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance, United States, 1991-1999. MMWR Surveill Summ 2003; 52: 1-8.
53. Treadwell SD, Thanvi B, Robinson TG. Stroke in pregnancy and the puerperium. Postgrad Med J 2008; 84: 238-245.
54. Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996; 335: 768-774.
55. Jeng JS, Tang SC, Yip PK. Stroke in women of reproductive age: Comparison between stroke related and unrelated to pregnancy. J Neurol Sci. 2004; 221(1-2): 25-29.
56. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1670.
57. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-1204.
58. Hamutal, M., Marei, S., Renate, H.: US20080187929A1 (2008)
59. Tietjen GE. The risk of stroke in patients with migraine and implications for migraine management. CNS Drugs 2005; 19 (8): 683-692.
60. Collaborative Group for the Study of Stroke in Young Women. Oral contraceptives and stroke in young women. JAMA 1975; 231: 718-722.
61. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischemic stroke in young women. BMJ 1995; 310: 830-833.
62. Donaghy M, Chang CL, Poulter N. European Collaborators of The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Duration, frequency, recency, and type of migraine and the risk of ischemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatr 2002; 73: 747-750.
63. Tǎnǎsescu R, Nicolau A, Caraiola S, et al. Antiphospholipid antibodies and migraine: A retrospective study of 428 patients with inflammatory connective tissue diseases. Rom J Intern Med 2007; 45(4): 355-363.
64. Chang CL, Donaghy M, Poulter NR, et al. Migraine and stroke in young women: Case-control study. BMJ 1999; 318 (7175): 13-18.
65. Dalla VG, Guindani M, Zavarise P, Griffini S, Pezzini A, Padovani A. Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache and relationship with clinical phenotype. J Headache Pain 2005; 6: 328-330.
66. Anzola GP, Magoni M, Guindani M, et al. Potential source of cerebral embolism in migraine with aura: A transcranial Doppler study. Neurology 1999; 52: 1622-1625.
67. Del SM, Angeli S, Leandri M, et al. Migraine with aura and right-to left shunt on transcranial Doppler: A case-control study. Cerebrovasc Dis 1998; 8: 327-330.
68. Jesurum JT, Fuller CJ, Velez CA, et al. Migraineurs with patent foramen ovale have larger right-to-left shunt despite similar atrial septal characteristics. J Headache Pain 2007; 8: 209-216.
69. Schwerzmann M, Nedeltchev K, Lagger F, et al. Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology 2005; 65(9): 1415-1418.
70. Janardhan V, Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The Framingham cohort and offspring study. Stroke 2004; 35(3): 736-741.
71. Brey, RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33: 2396-2401.
72. Touzé E, Rothwell PM. Heritability of ischaemic stroke in women compared with men: A genetic epidemiological study. Lancet Neurol 2007; 6(2): 125-133.
73. Touzé E, Rothwell PM. Sex differences in heritability of ischemic stroke: A systematic review and meta-analysis. Stroke 2008; 39(1): 16-23.
74. Gomberg-Maitland M, Wenger NK, Feyzi J, et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 2006; 27(16): 1947-1953.
75. Rundek T. Do women have worse outcome after stroke caused by intracranial arterial stenosis? Stroke 2007; 38: 2025.
76. Stensland-Bugge E, Bønaa KH, Joakimsen O. Age and sex differences in the relationship between inherited and lifestyle risk factors and subclinical carotid atherosclerosis: The Tromso study. Atherosclerosis 2001; 154(2): 437-448.
77. Sander K, Horn CS, Briesenick C, Sander D. INVADE Study Group. High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men. Stroke 2007; 38(11): 2881-2886.
78. DiTullio MR, Sacco RL, Savoia MT, Sciacca R, Homma S. Gender differences in the risk of ischemic stroke associated with aortic atheromas. Stroke 2000; 31: 2623-2627.
79. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women vs men (The Copenhagen City Heart Study). Am J Cardiol 2004; 94: 889-894.
80. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischaemic stroke and peripheral embolism in atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2005; 112: 1687-1691.
81. Nedeltchev K, Wiedmer S, Schwerzmann M, et al. Sex differences in cryptogenic stroke with patent foramen ovale. Am Heart J 2008; 156(3): 461-465.
82. Di Carlo A, Lamassa M, Baldereschi M, et al. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: Data from a multicenter multinational hospital-based registry. Stroke 2003; 34(5): 1114-1119.
83. Kent DM, Buchan AM, Hill MD. The gender effect in stroke thrombolysis. Of cases, controls, and treatment-effect modification. Neurology 2008; Epub ahead of print.
84. Ramani S, Byrne-Logan S, Freund KM, Ash A, Yu W, Moskowitz MA. Gender differences in the treatment of cerebrovascular disease. J Am. Geriatr Soc 2000; 48: 741-745.
85. Foerch C, Misselwitz B, Humpich M, Steinmetz H, Neumann-Haefelin T, Sitzer M. For the Arbeitsgruppe Schlaganfall Hessen. Sex disparity in the access of elderly patients to acute stroke care. Stroke 2007; 38: 2123.
86. Gargano JW, Wehner S, Reeves M. Sex differences in acute stroke care in a statewide stroke registry. Stroke. 2008; 39(1): 24-29.
87. Reid JM, Dai D, Gubitz GJ, Kapral MK, Christian C, Phillips SJ. Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital. Stroke 2008; 39(4): 1090-1095.
88. Glader EL, Stegmayr B, Norrving B, et al. Sex differences in management and outcome after stroke; A Swedish national perspective. Stroke 2003; 34: 1970.
89. Savitz SI, Schlaug G, Caplan L, Selim M. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke. Stroke 2005; 36(7): 1447-1451.
90. Hill MD, Kent DM, Hinchey J, et al. Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke 2006; 37(9): 2322-2325.
91. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: A pooled analysis of randomized clinical trials. Stroke 2005; 36(1): 62-65.
92. Elkind MS, Prabhakaran S, Pittman J, Koroshetz W, Jacoby M, Johnston KC. GAIN Americas Investigators. Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke. Neurology 2007; 68(11): 842-848.
93. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-453.
94. Barnett HJ, Taylor DW, Eliasziw M, et al. North American Symptomatic Carotid Endarterectomy Trail Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998; 339: 1415-1425.
95. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-1428.
96. Sarac TP, Hertzer NR, Mascha EJ, et al. Gender as a primary predictor of outcome after carotid endarterectomy. J Vasc Surg 2002; 35(4): 748-753.
97. Lane JS, Shekherdimian S, Moore WS. Does female gender or hormone replacement therapy affect early or late outcome after carotid endarterectomy. J Vasc Surg 2003; 37(3): 568-574.
98. Park BD, Aiello F, Dahn M, Menzoian J, Mavanur A. No gender influences on clinical outcomes or durability of repair following carotid angioplasty with stenting and carotid endarterectomy. Vasc Endovascular Surg 2008.
99. Theiss W, Hermanek P, Mathias K, et al. Predictors of death and stroke after carotid angioplasty and stenting. A subgroup analysis of the Pro-CAS Data. Stroke 2008.
100. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13): 1293-1304.
101. Berger JS, Roncaglioni MC, Avanzini F, pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313.
102. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008; 117: 2875-2883.
103. 4 formation: A randomized human trial. Arterioscler Thromb Vasc Biol 2006; 26: e14-e17.
104. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
105. Rabi DM, Khan N, Vallee M, Hladunewich MA, Tobe SW, Pilote L. Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol 2008; 24(6): 491-496.
106. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM 1996; 335: 1001-1009.
107. Ayala C, Croft JB, Greenlund KJ, et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age: 1995-1998. Stroke 2002; 33(5): 1197-1201.
108. Gargano JW, Wehner S, Reeves M. Sex differences in acute stroke care in a statewide stroke registry. Stroke 2008; 39(1): 24-29.
109. Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke 2000; 31(8): 1833-1837.
110. Gray LJ, Sprigg N, Bath PMW, et al. Sex differences in quality of life in stroke survivors. Data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke 2007; 38: 2960-2964.
111. Hall ED, Pazara KE, Linseman KL. Sex differences in post-ischemic neuronal necrosis in gerbils. J Cereb Blood Flow Metab 1991; 11: 292-298.
112. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. Stroke 1998; 29: 159-166.
113. Park EM, Cho S, Frys KA, et al. Inducibel nitric oxide synthase contributes to gender differences in ischemic brain injury. J Cereb Blood Flow Metab 2006; 26: 392-401.
114. Alkaed NJ, Crain BJ, Traystman RJ, Hurn PD. Estrogen mediated neuroprotection in reproductively senescent rats. Stroke 1999; 30: 274.
115. Jover T, Tanaka H, Calderone A, et al. Estrogen protects against global ischemia induced neuronal death and prevents activation of apoptotic signaling cascades in the hippocampal CA1. J Neurosci 2002; 22: 2115-2124.
116. Zhang YQ, Shi J, Rajakumar G, Day AL, Simpkins JW. Effects of gender and estrogen treatment on focal brain ischemia. Brain Res 1998; 784: 321-324.
117. Shughrue PJ, Merchenthaler I. Estrogen prevents the loss of CA1 hippocampal neurons in gerbils after ischemic injury. Neuroscience 2003; 116: 851-861.
118. Toung TJK, Traystamn RJ, Hurn PD. Estrogen mediated neuroprotection after experimental stroke in males. Stroke 1998; 29: 1666-1670.
119. Li H, Pin S, Zeng Z, Wang MM, Andreasson KA, McCullough LD. Sex differences in cell death. Ann Neurol 2005; 58(2): 317-321.
120. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD. Chronic behavioral testing after focal ischemia in the mouse: Functional recovery and the effects of gender. Exp Neurol 2004; 187: 94-104.
121. McClean J, Nunez JL. 17alpha-estradiol is neuro-protective in male and female rats in a model of early brain injury. Exp neurol 2008; 210(1): 41-50.
122. Gibson CL, Gray LJ, Murphy SP, Bath PMW. Estrogens and experimental ischemic stroke: A systematic review. J Cereb Blood Flow Metab 2006; 26: 1103-1113.
123. Yang SH, He Z, Wu SS, et al. 17-beta estradiol can reduce secondary ischemic damage and mortality of subarachnoid hemorrhage. J Cereb Blood Flow Metab 2001; 21: 174-181.
124. Liu R, Wang X, Liu Q, Yang SH, Simpkins JW. Dose dependence and therapeutic window for the neuroprotective effects of 17 beta estradiol when administered after cerebral ischemia. Nerosci Lett 2007; 415(3): 237-241.
125. Simpkins JW, Yang SH, Liu R, et al. Estrogen-like compounds for ischemic neuroprotection. Stroke 2004; 35(1): 2648-2651.
126. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infraction. J Am Med Assoc 2004; 291: 2669-2677.
127. Shearman AM, Cupples LA, Demissie S, et al. Association between Estrogen Receptor alpha gene variation and cardiovascular disease. J Am Med Assoc 2003; 290: 2263-2270.
128. Lehtimaki T, Laaksonen R, Mattila KM, et al. Oestrogen receptor gene variation is a determinant of coronary reactivity in healthy young men. Eur J Clin Invest 2002; 32: 400-404.
129. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation and the risk of stroke. Stroke 2005; 36: 2281-2282.
130. Lazaros L, Markoula S, Xita N, et al. Association of estrogen receptor alpha gene polymorphisms with stroke risk in patients with metabolic syndrome. Acta Neurol Scand 2008; 117: 186-190.
131. Strand M, Soderstrom I, Wiklund PG, et al. Estrogen receptor alpha gene polymorphisms and first ever intracerebral hemorrhage. Cerebrovasc Dis 2007; 24(6): 500-508.
132. Bos MJ, Schuit SC, Koudstaal PJ, Hofman A, Uitterlinden AG, Breteler MM. Variation in estrogen receptor alpha gene and risk of stroke. The Rotterdam Study. Stroke 2008.
133. Stirone C, Duckles SP, Krause DN. Multiple forms of estrogen receptor alpha in cerebral blood vessels: Regulation by estrogen. Am j Physiol Endocrinol Metab 2003; 284: e184-e192.
134. Dubal DB, Shughrue PJ, Wilson ME, Merchenthaler I, Wise PM. Estradiol modulates bcl-2 in cerebral ischemia: A potential role for estrogen receptors. J Neurosci 1999; 19: 6385-6393.
135. Sampei K, Goto S, Alkayed NJ, et al. Stroke in estrogen receptor alpha deficient mice. Stroke 2000; 31: 738-744.
136. Zhu Y, Bian Z, Lu P, et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002; 295: 505-508.
137. Wang L, Andersson S, Warner M, Gustafsson JA. Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci USA 2001; 98: 2792-2796.
138. Farr TD, Carswell HV, Gsell W, Macrae IM. Estrogen receptor beta agonist diarylpropiolnitrite (DPN) does not mediate neuroprotection in a rat model of permanent focal ischemia. Brain Res 2007; 1185: 275-282.
139. Filardo EJ, Thomas P. GPR30: A seven transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005; 16: 362-367.
140. Sangita, A.K., Singh, M.M., Jain, G.K., Murthy, P.S.R., Ray, S.: US20070244161A1 (2007).
141. Hill, E.N., Sancillo, F.D., Whittle, R.R.: US20070142307A1 (2007).
142. Jain, N.F., Mecielag, M.J., Murray, W.V., Ng, R.A., Sui, Z.: US20070142379A1 (2007).
143. Jackson, E.K., Tofovic, S.P., Dubey, R.K.: US20080171730A1 (2008).
144. Krejka J, Mariak Z, Nowacka A, Melham ER, Babikian VL. Influence of 17 beta estradiol on cerebrovascular impedence during menstrual cycle in women. J Neurol Sci 2004; 221: 61-67.
145. Krejka J, Siemkowicz J, Sawicka M, et al. Oscillations of cerebrovascular resistance throughout the menstrual cycle in healthy women. Ultrasound Obstet Gynecol 2003; 22: 627-632.
146. Brackley KJ, Ramsay MM, Broughton PF, Rubin PC. A longitudinal study of maternal bloodflow in normal pregnancy and the puerperium: Analysis of doppler waveforms using Laplace transform techniques. Br J Obstet Gynaecol 1998; 195: 68-77.
147. Skarsgard P, Van Breeman C, Laher I. Estrogen regulates myogenic tone in pressurized cerebral arteries by enhanced basal release of nitric oxide. Am J Physiol Heart Circ Physiol 1997; 273: h2248-h2256.
148. Pelligrino DA, Ye S, Tan F, Santizo RA, Feinstein DL, Wang Q. Nitric-oxide dependent pial arteriolar dilatation in the female rat: Effects of chronic estrogen depletion and repletion. Biochem Biophy Res Commun 2000; 269: 165-171.
149. Geary GG, Krause DN, Duckles SP. Estrogen reduces myogenic tone through a nitric oxide dependent mechanism in rat cerebral rteries. Am J Physiol Heart Circ Physiol 1998; 275: h292-h300.
150. Geary GG, Krause DN, Duckles SP. Gonadal hormones affect diameter of male rat cerebral arteries through endothelium dependent mechanisms. Am J Physiol Heart Circ Physiol 2000; 279: h610-h618.
151. McNeill AM, Kim N, Duckles SP, Kontos HA. Chronic estrogen treatment increase levels of endothelial nitric oxide synthase protein in rat cerebral microvessels. Stroke 1999; 30: 2186-2190.
152. Geary GG, Mcneill AM, Ospina JA, Krause DN, Korach KS, Duckles SP. Cerebrovascular NOS and cyclooxygenase are unaffected by estrogen in mice lacking estrogen receptor alpha. J Appl Phsiol 2001; 91: 2391-2399.
153. Ospina JA, Krause DN, Duckles SP. 17 beta estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 2002; 33: 600-605.
154. Stirone C, Boroujerdi A, Duckles SP, Krause DN. Estrogen receptor activation of phopshoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: Rapid and Long term effects. Mol Pharmacol 2005; 67: 105-113.
155. Chambilss KL, Shaul PW. Rapid activation of endothelial NO synthase by estrogen: Evidence for stroid receptor fast-action complex (SRFC) in caveolae. Steroids 2002; 67: 413-419.
156. Xu HL, Galea E, Santizo RA, Baughman VL, Pelligrino DA. The key role of caveolin -1 in estrogen mediated regulation of endothelial nitric oxide synthase in cerebral arterioles in vivo. J Cereb Blood Flow Metab 2001; 21: 907-913.
157. Golding EM, Kepler TE. Role of estrogen in modulating EDHF-mediated dilatations in the female rat middle cerebral artery. Am J Physiol Heart Circ Physiol 2001; 280: h2417-h2423.
158. Salom JB, Burguete MC, Perez-Asension FJ, Torregrosa G, Albroch E. Relaxant effects of 17 beta estradiol in cerebral arteries through calcium entry inhibition. J Cereb Blood Flow Metab 2001; 21: 422-429.
159. Polderman KH, Stehouwer CDA, van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1993; 118: 429-432.
160. Saija A, Princi P, D'Amico N, De Pasquale R, Costa G. Aging and sex influence the permeability of the blood brain barrier in the rat. Life Sci 1990; 47: 2261-2267.
161. Takeda-Matsubara Y, Nakagami H, Iwai M, et al. Estrogen activates phosphatases and antagonizes growth promoting effect of angiotensin II. Hypertension 2002; 39: 41-45.
162. Dubey RK, Gillespie DG, Imthurn B, Roselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999; 33: 177-182.
163. Han Y, Liang M, Kang J, et al. Estrogen-eluting stent implantation inhibits neointimal formation and extracellular signal-regulated kinase activation. Catheter Cardiovasc Interv 2007; 70(5): 647-653.
164. Ardlett AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, Hurn PD. Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor alpha in a rodent experimental stroke model. Stroke 2005; 36: 337-341.
165. Zhao L, Wu TW, Brinton RD. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased bcl-2 expression in primary hippocampal neurons. Brain Res 2004; 1010: 22-34.
166. Wu TW, Wang JM, Chen S, Brinton RD. 17 Beta estrogen induced calcium influx via L type calcium channels activates the Src/ERK/cyclic AMP response element binding protein signal pathway and bcl-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen induced neuroprotection. Neurosci 2005; 135: 59-72.
167. Rau SW, Dubal DB, Bottner M, Gerhold LM, Wise PM. Estrogen attenuates programmed cell death after stroke like injury. J Neurosci 2003; 23: 11420-11426.
168. Devoto VM, Giusti S, Chavez JC, de Plazas SF. Hypoxia induced apoptotic cell death is prevented by oestradiol via estrogen receptors in the developing central nervous system. J Neuroendocrinol 2008; 20(3): 375-380.
169. Wang R, Zhang QZ, Han D, Lu Q, Zhang GY. Inhibition of MLK3-MKK4/7-JNK1/ 2 pathway by Akt 1 in exogenous estrogen induced neuroprotection against global cerebral ischemia by a nongenomic mechanism in male rats. J Neurochem 2006; 99(6): 1543-1554.
170. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery. Cell 1997; 91: 231-241.
171. Cardonna-Gomez GP, Mendez P, Don Carlos LL, Azcoitia I, Garcia-Segura LM. Interactions of estrogens and insulin like growth factor I in the brain: implications for neuroprotection. Brain Res Rev 2001; 37: 320-334.
172. Crosby KM, Connell BJ, Saleh TM. Estrogen limits ischemic cell death by modulating caspase-12 mediated apoptotic pathways following middle cerebral artery occlusion. Neurosci 2007; 146(4): 1524-1535.
173. Santagati S, Melcangi RC, Celotti F, Martini L, Maggi A. Estrogen receptor is expressed in different types of glial cells in culture. J Neurochem 1994; 63: 2058-2064.
174. Dhandapani K, Wade FM, Mehesh WB, Brann DW. Astrocyte derived transforming growth factor Beta mediates the neuroprotective effects of 17 beta estrogen: Involvement of non-classical genomic signaling pathways. Endocrinology 2005; 146: 2749-2759.
175. Pawlak J, Brito V, Kuppers E, Beyer C. regulation of glutamate transporter GLAST and GLT 1 expression in astrocytes by estrogen. Brain Res Mol Brain Res 2005; 138: 1-7.
176. Tripanchkul W, Sripanichkulchai K, Finkelstein DI. Estrogen down regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. Brain Res 2006; 1084: 28-37.
177. Kii N, Adachi N, Liu K, Arai T. Acute effects of 17 beta estrogen on oxidative stress in ischemic rat striatum. J Neurosurg Anesthiol 2005; 17: 27-32.
178. Chan PH. Role of oxidants in ischemic brain damage. Stroke 1996; 27: 1124-1129.
179. Brannvall K, Korhonen L, Lindholm D. Estrogen receptor dependent
180. Tanapat P, Hastings NB, Gould E. Ovarian steroids influence cell proliferation in the dentate gyrus of the adult female rat in a dose and time dependent manner. J Comp Neurol 2005; 481: 252-265.
181. Wang JM, Liu L, Brinton RD. Estradiol 17 beta-induced human neural progenitor cell proliferation is mediated by an estrogen receptor beta-phosphorylated extracellularly regulated kinase pathway. Endocrinology 2008; 149: 208-218.
182. Strehlow K, Rotter S, Wassman S, et al. Modulation of antioxidant enzyme expression and function by estrogens. Circ Res 2003; 93: 170-177.
183. Stirone C, Duckles SP, Krause DN, Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 2005; 68: 959-965.
184. Okumura M, Iwai M, Ide A, Mogi M, Ito M, Horiuchi M. Sex difference in vascular injury and vasoprotective effects of valsartan are related to differential AT2 receptor expression. Hypertension 2005; 46: 577-583.
185. Silva-Antonialli MM, Tostes RC, Fernandes L, et al. A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than male spontaneously hypertensive rats. Cardiovasc Res 2004; 62: 587-593.
186. Dean SA, Tan J, O'Brien ER, Leenen FH. 17 beta estradiol downregulates tissue angiotensin converting enzyme and Ang II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 2005; 288: r759-r766.
187. Xu X, Xiao JC, Luo LF, et al. Effects of ovariectomy and 17 beta estradiol treatment on the renin-angiotensin system, blood pressure, and endothelial ultrastructure. Int J Cardiol 2007.
188. Rogers JL, Mitchell AR, Maric C, Sandberg K, Myers A, Mulroney SE. Effect of sex hormones on renal estrogen and angiotensin type I receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol 2007; 292(2): r794-r799.
189. Girouard H, Lessard A, Capone C, Milner TA, Iadecola C. The neurovascular dysfunction induced by Angiotensin II in the mouse neocortex is sexually dimorphic. Am J Phsiol Heart Circ Physiol 2008; 294(1): h156-h163.
190. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004; 286: r233-r249.
191. Stein DG, Wright DW, Kellerman AL. Does progesterone have neuroprotective properties? Ann Emerg Med 2008; 51(2): 164-172.
192. Cutler SM, Cekic M, Miller DM, Wali B, VanLandingham JW, Stein DG. Progesterone improves acute recovery after traumatic injury in the aged rat. J Neurotrauma 2007; 24(9): 1475-1486.
193. Morali G, Letechipia-Vallejo G, Lopez-Loeza E, et al. Postiscemic administration of progesterone in rats exerts neuroprotective effects on the hippocampus. Neurosci Lett 2005; 382: 286-290.
194. Jiang N, Chopp M, Stein D, et al. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Res 1996; 735: 101-107.
195. Ohtsuki S, Tomi M, Hata T, et al. Dominant expression of androgen receptors and their functional regulation of organic anion transporter 3 in rat brain capillary endothelial cells: Comparison of gene expression between the blood-brain and retinal barriers. J Cell Physiol 2005; 204: 896-900.
196. Gonzales RJ, Ghaffari AA, Duckles SP, Krause DN. Testosterone treatment increases thromboxane function in rat cerebral arteries. Am J Physiol Heart Circ Physiol 2005; 289: h578-h585.
197. Penotti M, Sironi L, Cannata L, et al. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil Steril 2001; 76: 235-240.
198. Fujimoto R, Morimoto I, Morita E, Sugimoto H, Ito Y, Eto S. Androgen receptors, 5 alpha reductase activity and androgen dependent proliferation of smooth muscle cells. J Steroid Biochem Mol Biol 1994; 50: 169-174.
199. Singh H, Cheng J, Deng H, et al. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetranoic acid synthesis contribute to endothelial dysfunction in androgen induced hypertension. Hypertension 2007; 50: 123-129.
200. Omura T, Tanaka Y, Miyata N, et al. Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke 2006; 37: 1307-1313.
201. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary artery atherosclerosis and atherosclerosis related impairment of vascular responsiveness. Arterio Thromb Vasc Biol 1995; 15: 562-570.
202. Fukui M, Kitagawa Y, Nakamura N, et al. Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. Atherosclerosis 2005; 181(2): 339-344.
203. Tetsuro, S., Samuel, W.: US20080181873A1 (2008).
204. Denton M, Prus S, Walters V. Gender differences in health: A Canadian study of the psychosocial, structural and behavioral determinants of health. Soc Sci Med 2004; 58: 2585-2600.
205. Rieker PP, Bird CE. Rethinking gender differences in health: Why we need to integrate social and biological perspectives. J Gerontol B Psychol Sci Soc Sci 2005; 60(2): 40-47.
206. Möller-Leimkühler AM. Gender differences in cardiovascular disease and comorbid depression. Dialogues Clin Neurosci 2007; 9(1): 71-83.
207. McDonough P, Walters V. Gender and health. Reassessing patterns and explanations. Soc Sci Med 2001; 52: 547-559.